A Circuit Mechanism for Neurodegeneration  by Roselli, Francesco & Caroni, Pico
Bmp8b treatment of brown adipocytes
has also been shown to lead to an
increase in AMPK activation (Whittle
et al., 2012). Though pharmacological
activators of AMPK, especially metformin,
are already in clinical use, activators of
the noncanonical hedgehog pathway
and modulators of these other develop-
mental gene pathways may serve as
targets for new therapeutics for diabetes
and obesity.
The current study from Teperino et al.
adds to the burgeoning body of data
that developmental genes and signaling
pathways play integral roles not only in
the formation, but also in the function, of
brown fat, white fat, and muscle. Thus,
these pathways regulate not only devel-
opment of these tissues, but also the
metabolism of the fully differentiated cells.
These findings suggest that modulation of
these developmental genes and their250 Cell 151, October 12, 2012 ª2012 Elsevisignaling pathways has therapeutic impli-
cations across a wide array of disease
states, including cancer and metabolic
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How deficiency in SMN1 selectively affects motoneurons in spinal muscular atrophy is poorly
understood. Here, Imlach et al. and Lotti et al. show that aberrant splicing of Stasimon in cholinergic
sensory neurons and interneurons leads to motoneuron degeneration, suggesting that altered
circuit function may underlie the disorder.Neurological disorders with a genetic
basis usually involve the degeneration of
distinct cellular subpopulations within
the central nervous system (CNS). The
factors shaping the differential sensitivity
of neurons to the same genetic insult are
poorly understood. Sensitivity to disease
may be cell autonomous, with the partic-
ular molecular makeup of one subpopu-
lation of neurons being responsible for
the phenotype. In an alternative scenario
that has received much less attention so
far, a subpopulation of neurons might beprone to degeneration due to alterations
in the function of the neuronal circuits
that impinge onto those neurons. In the
latter view, degenerating neurons might
represent the ‘‘weakest link’’ within a
circuit, although they are not primarily
affected by the genetic mutation. The
circuit scenario further implies that
distinct dysfunction pathways affecting
the same circuit might produce compa-
rable patterns of neurodegeneration. In
this issue of Cell, Imlach et al. (2012) and
Lotti et al. (2012) provide evidence ina Drosophila model of spinal muscular
atrophy (SMA) that motoneuron dysfunc-
tion is in fact due to impairments in the
function of sensory neurons and interneu-
rons (Figure 1).
SMA is a frequent autosomal-recessive
motoneuron disorder characterized by
the degeneration of a motoneurons due
to inactivation of the survival of motor
neuron 1 (SMN1) gene. SMN1 protein
is critically involved in the biogenesis
of small nuclear ribonucleoproteins
(snRNPs), and SMN1 loss extensively
Figure 1. Circuit Basis for Selective Degeneration of Motoneurons in a Drosophila Model
of SMA
Motoneurons receive indirect excitatory inputs from cholinergic sensory and cholinergic spinal inter-
neurons. Under wild-type conditions, normal levels of SMN protein ensure correct splicing and proper
levels of Stasimon mRNA and proper excitation of the cholinergic neurons and functional motoneurons
(left). Upon loss of SMN, residual SMN protein from amaternal mRNA pool is insufficient to properly splice
Stasimon transcript, leading to reduced accumulation of its mRNA (right). This leads to reduced excitation
of the cholinergic neurons and to motoneuron degeneration.affects RNA splicing. Complete loss of
SMN1 is lethal, but in most tissues, small
amounts of SMN2 protein are sufficient
to ensure proper function, and only moto-
neurons appear to degenerate in SMA.
Motoneurons have thus appeared to
be plausible candidates for cell-autono-
mous neurodegeneration. Their large cell
bodies, extremely long axons, and large
neuromuscular junctions (NMJs) impose
high metabolic and trafficking demands,
which might provide sensitive targets for
genetic mutations. In SMA mice, deletion
of SMN1 causes moderate loss of moto-
neurons but profound motor impairments
and lethality at 2 weeks of age; re-
expression of SMN1 throughout the CNS
prevents motoneuron degeneration (Gav-
rilina et al., 2008). However, restoration of
SMN1 levels specifically in motoneurons
does not effectively rescue the SMA
phenotype; although synaptic abnormali-
ties at the NMJ are rescued, survival isonly extended by a few days (Martinez
et al., 2012; Gogliotti et al., 2012). Along
similar lines, loss of SMN1 restricted to
motoneurons only produces a partial
SMA-like phenotype (Park et al., 2010).
These findings have suggested that
SMN1 depletion in cells other than moto-
neurons might have an important role in
the pathogenesis of SMA.
Imlach et al. (2012) now study these
questions in a Drosophila model in which
the SMN1 ortholog SMN is deleted ubiq-
uitously. Mutant flies exhibited moto-
neuron hyperexcitability, altered rhythmic
motor activity, and muscular atrophy at
larval stage. Panneuronal restoration of
SMN fully rescues these phenotypes.
Surprisingly, re-expression of SMN in
motoneurons, in all glutamatergic neu-
rons, or in inhibitory neurons entirely fails
to attenuate the phenotype of mutant
flies. In contrast, re-expression of SMN
in cholinergic neurons fully rescuesCell 151all mutant phenotypes. SMN rescue in
bipolar dendrite (bd) and type I multiden-
dritic (md) sensory (cholinergic) neurons
normalizes muscle size and NMJ neuro-
transmission, whereas full rescue of loco-
motion requires re-expression of SMN in
additional cholinergic subpopulations.
SMN deletion in cholinergic neurons
causes an SMN-related phenotype by
reducing the excitability of these neurons.
Thus, depressing the activity of cholin-
ergic neurons fully reproduces the phe-
notypic consequences of SMN deletion,
and increasing cholinergic neuron ex-
citation by genetic or pharmacological
approaches is sufficient to rescue all
SMN-related phenotypes. SMN depletion
therefore primarily affects the function
of a subpopulation of cholinergic sen-
sory and spinal interneurons, whose de-
creased excitatory drive causes moto-
neuron dysfunction.
In the companion study, Lotti et al.
(2012) investigate the molecular conse-
quences of reduced SMN protein in
Drosophila. Building on the preferential
reduction in the minor snRNP class re-
ported for SMA mice, Lotti et al. (2012)
first show that SMN depletion dramati-
cally impairs U12 splicing in vitro and
then use the Drosophila model to identify
relevant target genes aided by the fact
that there are only 23 putative U12 introns.
Eighteen out of 23 introns exhibit aberrant
splicing, and seven out 18 tested candi-
date genes exhibit reduced mature mes-
senger RNA (mRNA) levels. Knockdown
of one of them (Stasimon), but not of any
of the other genes, causes an NMJ
phenotype closely resembling loss of
SMN. Stasimon knockdown in motoneu-
rons does not affect NMJ function,
whereas its knockdown in cholinergic
neurons reproduces SMN-related pheno-
types. Likewise, re-expressing Stasimon
in SMN mutant motoneurons does not
affect the SMN phenotype, whereas re-
expression of Stasimon in cholinergic
neurons fully restores NMJ activity and
muscle size. Overall, locomotor and
motor rhythms are not rescued, suggest-
ing that further defects upon SMN deple-
tion in cholinergic neurons account for the
residual phenotypes. Lotti et al. (2012)
further provide evidence that Stasimon
splicing is severely affected in motoneu-
rons and dorsal root ganglia neurons
in a mouse model of SMA. Stasimon, October 12, 2012 ª2012 Elsevier Inc. 251
expression also rescues motor axon
disruptions observed upon SMN knock-
down in zebrafish. Although the function
of Stasimon is currently unknown, it is
highly conserved and related to Golgi
SNARE proteins, suggesting that it might
be involved in intracellular trafficking.
Taken together, these two studies sug-
gest that splicing alterations in Drosophila
Stasimon within restricted subpopula-
tions of cholinergic neurons suppresses
the excitation of these neurons, which in
turn leads to motoneuron dysfunction.
In findings reminiscent of these circuit
dysfunction results in Drosophila, mono-
synaptic connections between proprio-
ceptive (sensory) neurons and motoneu-
rons are severely affected and then
lost in SMA mice (Mentis et al., 2011).
The upshot of these new discoveries is
that the degeneration of motoneurons in
SMA might not be a cell-autonomous
consequence of SMN loss but is instead
the outcome of a network dysfunction in
which motoneurons are particularly sen-
sitive to diminished excitation. Whether
motoneuron degeneration results from
a deficit in excitation or from a homeo-
static increase in excitability remains to
be determined. Although circuit contri-
butions provide the main mechanism
leading to motoneuron dysfunction in
Drosophila larvae lacking SMN, in SMA
mice, marked rescue has been reported
by SMN1 re-expression in motoneurons
only or in peripheral tissue (Gogliotti252 Cell 151, October 12, 2012 ª2012 Elseviet al., 2012; Martinez et al., 2012; Hua
et al., 2011). Possible interactions
between circuit-based mechanisms and
either cell-autonomous or systemic ef-
fects of SMN1 deletion deserve further
investigation. Alternatively, loss of SMN
might primarily affect cholinergic neu-
ron function. Thus, whereas mammalian
motoneurons (and a few spinal inter-
neuron subpopulations) are choliner-
gic, motoneurons are glutamatergic in
Drosophila. Conversely, the sensory and
spinal interneurons affected by the
absence of SMN in flies are cholinergic.
Accordingly, Stasimon deficits might
affect the function of distinct cholinergic
neuron subpopulations but produce
comparable circuit-level disruptions and
motoneuron degeneration in vertebrates
and flies.
Circuit mechanisms may also be
relevant to other neurodegenerative dis-
eases. In Huntington disease, the de-
generation of medium spiny neurons
is greatly accelerated by a dearth of
cortex-derived BDNF (Milnerwood and
Raymond, 2010). In Alzheimer disease,
network dysfunction may be the earliest
mechanism accounting for cognitive im-
pairment (Verret et al., 2012). The notion
that the distinct neuronal sensitivities
might result from circuit-level dysfunc-
tions indirectly affecting those more
vulnerable neurons (alongwith cell-auton-
omous features) may thus provide a
general conceptual framework to eluci-er Inc.date mechanisms of disease in neurode-
generation.REFERENCES
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